Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159702 · ClinicalTrials.gov registry record · Phase 2
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03159702 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 43 participants.
The verdict
NCT03159702, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplantation. In addition, the study evaluates the one-year progression-free survival of patients undergoing this treatment.
Interventions
- DRUG Fludarabine
- RADIATION Total Body Irradiation
- DRUG Evomela
- OTHER Haploidentical Hematopoietic Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03159702
The ClinicalTrials.gov registry entry for NCT03159702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT03159702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03159702 about?
NCT03159702 is a clinical study titled "Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation". This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplantation. In addition, the study evaluates the one-ye...
What is the current status of trial NCT03159702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2017-12-08. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT03159702?
The interventions under investigation include: Fludarabine (DRUG), Total Body Irradiation (RADIATION), Evomela (DRUG), Haploidentical Hematopoietic Cell Transplantation (OTHER).
Who is sponsoring clinical trial NCT03159702?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.